Multikinase inhibitors: A new option for the treatment of thyroid cancer

Nature Reviews Endocrinology

Volumn 7, Issue 10, 2011, Pages 617-624

  Gild, Matti L ^a   Bullock, Martyn ^a   Robinson, Bruce G ^a   Clifton Bligh, Roderick ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; B RAF KINASE; CARBOPLATIN; DACARBAZINE; LENVATINIB; LEVOTHYROXINE; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PAZOPANIB; RADIOACTIVE IODINE; RAPAMYCIN; RDEA 119; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB; XL 184;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CYTOPENIA; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LEUKOPENIA; MELANOMA; MITOGENESIS; MOUTH PAIN; MUCOSA INFLAMMATION; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENT DISORDER; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THYROID CANCER; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT REDUCTION;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 80053136401     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.141     Document Type: Review

References (70)

1. National Cancer Institute. Surveillance Epidemiology and End Results [online], http://seer.cancer.gov/statfacts/html/thyro.html#incidence-mortality (2011).
2. DeLellis, R. A., Lloyd, R. V., Heitz, P. U. & Eng, C. (Eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. (IARC Press, Lyon, 2004).
3. Mazzaferri, E. L. & Jhiang, S. M. Differentiated thyroid cancer long-term impact of initial therapy. Trans. Am. Clin. Climatol. Assoc. 106, 151-168 (1995).
4. Eustatia-Rutten, C. F. et al. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 313-319 (2006). (Pubitemid 43069155)
5. Dohan, O. et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 24, 48-77 (2003).
6. Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discovery 2, 296-313 (2003). (Pubitemid 37361688)
7. Mulligan, L. M. et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460 (1993). (Pubitemid 23179393)
8. Learoyd, D. L., Messina, M., Zedenius, J. & Robinson, B. G. Molecular genetics of thyroid tumors and surgical decision-making. World J. Surg. 24, 923-933 (2000). (Pubitemid 30461213)
9. Kondo, T., Ezzat, S. & Asa, S. L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6, 292-306 (2006).
10. Fusco, A. et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328, 170-172 (1987). (Pubitemid 17108219)
11. Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245-262 (2005). (Pubitemid 40896444)
12. Ricarte-Filho, J. C. et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 Cancer Res. 69, 4885-4893 (2009).
13. Wang, Y. et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol 3 kinase/akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab. 92, 2387-2390 (2007). (Pubitemid 46997152)
14. Segouffin-Cariou, C. & Billaud, M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J. Biol. Chem. 275, 3568-3576 (2000). (Pubitemid 30083066)
15. Diallo-Krou, E. et al. Paired box gene 8-peroxisome proliferator- activated receptor-γ fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 150, 5181-5190 (2009).
16. Verfaillie, C. M. Biology of chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. 12, 1-29 (1998). (Pubitemid 28119349)
17. Stein, B. et al. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clinical Therapeutics 32, 804-820 (2010).
18. Hochhaus, A. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303-2309 (2007). (Pubitemid 46425867)
19. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). (Pubitemid 34716871)
20. Smalley, K. S. & Sondak, V. K. Melanoma-an unlikely poster child for personalized cancer therapy. N. Engl. J. Med. 363, 876-878 (2010).
21. Wellbrock, C. et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. Plos ONE 3, e2734 (2008).
22. Hoeflich, K. P. et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66, 999-1006 (2006). (Pubitemid 43165968)
23. Livingstone, E., Zimmer, L., Piel, S. & Schadendorf, D. PLX4032: does it keep its promise for metastatic melanoma treatment? Expert Opin. Investig. Drugs 19, 1439-1449 (2010).
24. Hauschild, A. et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830 (2009).
25. Smalley, K. S. PLX-4032, a small molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr. Opin. Investig. Drugs 11, 699-706 (2010).
26. Flaherty, K. et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer [abstract]. J. Clin. Oncol. 27 (Suppl.), a9000 (2009).
27. Flaherty, K. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
28. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
29. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
30. Adjei, A. A. et al. Phase I pharmokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008).
31. Infante, J. R. et al. Safety and efficacy results from the first in human study of the oral MEK1/2 inhibitor GSK1120212 [abstract]. J. Clin. Oncol. 28, a2503 (2010).
32. Infante, J. R. et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract]. J. Clin. Oncol. 29, a8503 (2011).
33. Kaplan, F. M., Shao, Y., Mayberry, M.M & Aplin, A. E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 30, 366-371 (2011).
34. Sherman, S. I. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab. 94, 1493-1499 (2009).
35. Perez, C. A., Santos, E. S., Arango, B. A., Raez, L. E. & Cohen, E. E. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck doi:101002/hed.21755
36. Carlomagno, F. et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62, 7284-7290 (2002). (Pubitemid 36025251)
37. Vitagliano, D. et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr. Relat. Cancer 18, 1-11 (2011).
38. Akeno-Stuart, N. et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 67, 6956-6964 (2007). (Pubitemid 47105543)
39. Koga, K. et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci. 101, 941-947 (2010).
40. Henderson, Y. C. et al. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin. Cancer Res. 14, 4908-4914 (2008).
41. Carlomagno, F. et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 98, 326-334 (2006). (Pubitemid 43338212)
42. Verbeek, H. H. et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J. Clin. Endocrinol. Metab. 96, E991-E995 (2011).
43. Wells, S. A. Jr et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28, 767-772 (2010).
44. Robinson, B. G., Paz-Ares, L., Krebs, A., Vasselli, J. & Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95, 2664-2671 (2010).
45. Wells, S. A. Jr et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA) [abstract]. J. Clin. Oncol. 28, a5503 (2010).
46. Polverino, A. et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 66, 8715-8721 (2006). (Pubitemid 44449188)
47. Schlumberger, M. J. et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol. 27, 3794-3801 (2009).
48. Cohen, E. E. et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol. 26, 4708-4713 (2008).
49. Lam, E. T. et al. Phase II clinical triial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol. 28, 2323-2330 (2010).
50. Kurzrock, R. et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666 (2011).
51. Liu, D. & Xing, M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-?B pathways. Thyroid 18, 853-864 (2008).
52. Liu, D., Xing, J., Trink, B. & Xing, M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int. J. Cancer 127, 2965-2973 (2010).
53. Salvatore, G. et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer Res. 12, 1623-1629 (2006).
54. Henderson, Y. C., Ahn, S. H., Kang, Y. & Clayman, G. L. Sorafenib potently inhibits papillary thyroid carcinomas harbouring RET/PTC1 rearrangement. Clin. Cancer Res. 14, 4908-4914 (2008).
55. Liu, R. et al. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J. Clin. Endocrinol. Metab. 96, E577-E585 (2011).
56. Liu, D., Xing, J., Trink, B. & Xing, M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int. J. Cancer 127, 2965-2973 (2010).
57. Jin, N., Jiang, T., Rosen, D. M., Nelkin, B. D. & Ball, D. W. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 94, 4107-4112 (2009).
58. Xing, J., Liu, R., Xing, M. & Trink, B. The BRAF T1799A mutation confers sensitivity of thyroid cancer cells to the BRAF V600E inhibitor PLX4032 (RG7204).Biochem. Biophys. Res. Commun. 404, 958-962 (2011).
59. Sherman, S. I. et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 359, 31-42 (2008). (Pubitemid 351931094)
60. Bass, M. B. et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab. 2010, 5018-5027 (2010).
61. Kloos, R. T. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27, 1675-1684 (2009).
62. Gupta-Abramson, V. et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26, 4714-4719 (2008).
63. Ahmed, M. et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer-a phase II study in a UK based population. Eur. J. Endocrinol. 165, 315-322 (2011).
64. Cabanillas, M. E. et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J. Clin. Endocrinol. Metab. 95, 2588-2595 (2010).
65. Carr, L. L. et al. Phase II study of daily sunitinib in FDG PET positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 16, 5260-5268 (2010).
66. Bible, K. C. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 11, 962-972 (2010).
67. Sherman, S. I. et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) [abstract]. J. Clin. Oncol. 29, a5503 (2011).
68. Riesco-Eizaguirre, G., Gutirrez-Martínez, P., García- Cabezas, M. A., Nistal, M. & Santisteban, P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr. Relat. Cancer 13, 257-269 (2006).
69. Hoftijzer, H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake in patients with differentiated thyroid cancer. Eur. J. Endocrinol. 161, 923-931 (2009).
70. Hong, D. S. et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J. Clin. Endocrinol. Metab. 96, 997-1005 (2011).